drugset / Trial / NCT07002216
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD) in patients with Stage 2 B-IV Hodgkin Lymphoma (HL) with an exploratory objective to assess the clinical utility of Circulating tumor DNA (ctDNA) as a biomarker for minimal residual disease (MRD) and depth of treatment response.
Timeline
- Start
- 2025-07-15
- Primary completion
- 2030-07-15
- Completion
- 2030-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brentuximab Vedotin | Monoclonal antibody | 1.8 mg/kg | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 1250 mg/m2 | Intravenous |
| Subject | Dacarbazine | Small molecule | 250 mg/m2 | Intravenous |
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Doxorubicin | Other / unclassified | 40 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 150 mg/m2 | Intravenous |